Ask AI
ProCE Banner Series

Advances in Bispecific Antibody Therapy for Multiple Myeloma: Strategies to Personalize Treatment and Elevate Patient Outcomes

Join us in person or online for this interactive symposium in conjunction with EHA 2026, in which an expert panel of hematologic oncologists will discuss the global landscape of bispecific antibodies in multiple myeloma. 

Please note that you must be registered for the EHA 2026 Congress to attend this symposium in person or virtually. You may register at:  https://ehaweb.org/connect-network/eha2026-congress/eha2026-registration

  AMA
Who Should Attend

This activity has been designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals who care for patients with multiple myeloma. 

All Events

Advances in Bispecific Antibody Therapy for Multiple Myeloma: Strategies to Personalize Treatment and Elevate Patient Outcomes

Upcoming Events

June

13

2026

7:45 AM - 9:30 AM Central European Time (CET)

In-person

Stockholmsmässan, Massvagen 1, 125 30 Alvsjö, Stockholm

8:00 AM - 9:30 AM Central European Time (CET)

Virtual

Topics

Multiple Myeloma

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of hematologists, oncologists, and other healthcare professionals in the personalized integration of bispecific antibodies into therapeutic plans that improve outcomes for patients with multiple myeloma.

Target Audience
This activity has been designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals who care for patients with multiple myeloma. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate emerging safety and efficacy data on new bispecific antibody therapies into the personalized treatment of patients with multiple myeloma 

  • Identify patients with multiple myeloma who may be eligible for ongoing clinical trials evaluating currently available and emerging bispecific antibodies

  • Manage and mitigate adverse events associated with bispecific antibody treatment in patients with multiple myeloma

  • Compare safety and efficacy profiles among available bispecific antibodies to individualize therapy selection for patients with relapsed/refractory multiple myeloma

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191